<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Oxford Biomedica Plc — News on 6ix</title>
<link>https://6ix.com/company/oxford-biomedica-plc</link>
<description>Latest news and press releases for Oxford Biomedica Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/oxford-biomedica-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e9a178dffbe2df129e59.webp</url>
<title>Oxford Biomedica Plc</title>
<link>https://6ix.com/company/oxford-biomedica-plc</link>
</image>
<item>
<title>Launch of viral vector fast-track offering</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/launch-of-viral-vector-fast-track-offering</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/launch-of-viral-vector-fast-track-offering</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>Oxford Biomedica PLC has launched a new fast-track offering for lentiviral and adeno-associated viral vector platforms, designed to accelerate GMP manufacturing timelines by up to nine months. This expedited service, available for eligible programmes utilizing the company's proprietary inAAVate™ and LentiVector™ platforms, can reduce the pathway to GMP manufacture for AAV vectors from approximately 15 months to as little as seven months, and for lentiviral vectors from 12-18 months to nine month</description>
</item>
<item>
<title>Grant of Awards</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/grant-of-awards-4</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/grant-of-awards-4</guid>
<pubDate>Wed, 08 Apr 2026 16:18:00 GMT</pubDate>
<description>Oxford Biomedica PLC announced on April 8, 2026, the grant of nil-cost share options under its 2024 Long Term Incentive Plan and Deferred Bonus Plan to several senior executives, including Dr. Frank Mathias and Dr. Lucinda Crabtree. These grants, effective April 7, 2026, are part of the re-instatement of originally intended award levels and are subject to performance conditions and post-vesting holding periods. The 2026 LTIP metrics are set at 60% revenue and 40% Operating EBITDA margin, assesse</description>
</item>
<item>
<title>2026 Annual General Meeting notification</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/2026-annual-general-meeting-notification</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/2026-annual-general-meeting-notification</guid>
<pubDate>Mon, 30 Mar 2026 14:30:00 GMT</pubDate>
<description>Oxford Biomedica PLC has announced that the Notice of Annual General Meeting and the 2025 Annual Report and Accounts are being mailed to shareholders today, with both documents also available on the company's website. The AGM is scheduled to take place on May 7, 2026, at 3:00 p.m. at their Oxford offices. This notification is a standard procedural announcement and does not contain specific financial performance data for the current period.
Disclaimer*</description>
</item>
<item>
<title>Preliminary results for the year ended 31 Dec 2025</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/preliminary-results-for-the-year-ended-31-dec-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/preliminary-results-for-the-year-ended-31-dec-2025-1</guid>
<pubDate>Thu, 26 Mar 2026 07:00:00 GMT</pubDate>
<description>Oxford Biomedica PLC reported strong preliminary results for the year ended 31 December 2025, achieving revenue growth of 33% to £170.9 million and reporting an Operating EBITDA profit of £8.1 million, a significant improvement from the previous year's loss. This profitability was bolstered by a one-off gain from the acquisition of a commercial-scale viral vector manufacturing facility in Durham, North Carolina. The company also saw its revenue backlog increase by approximately 36% to £204 milli</description>
</item>
<item>
<title>Licensing agreement with VVMF</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/licensing-agreement-with-vvmf</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/licensing-agreement-with-vvmf</guid>
<pubDate>Wed, 18 Mar 2026 07:00:00 GMT</pubDate>
<description>Oxford Biomedica PLC has entered into a licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), granting VVMF a worldwide, non-exclusive licence to OXB's proprietary inAAVate™ platform know-how and intellectual property, with an option for its LentiVector™ platform. This five-year agreement will provide OXB with a low single-digit million licence fee and potential future payments, reinforcing OXB's global reach and positioning VVMF to capture demand in the APAC region.
</description>
</item>
<item>
<title>Admission to Trading</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/admission-to-trading-11</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/admission-to-trading-11</guid>
<pubDate>Mon, 09 Mar 2026 07:53:00 GMT</pubDate>
<description>Oxford Biomedica PLC has announced the admission to trading of 92,381 ordinary shares of 50p each on the London Stock Exchange's Main Market. These new shares, which are fungible with existing shares, were allotted under the company's Long Term Incentive Plan, Sharesave Scheme, and Employee Share Option Scheme between January 21, 2026, and March 2, 2026. Following this admission, the total number of ordinary shares in issue for Oxford Biomedica PLC is now 120,873,439.
Disclaimer*</description>
</item>
<item>
<title>Admission to Trading Application</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/admission-to-trading-application</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/admission-to-trading-application</guid>
<pubDate>Wed, 04 Mar 2026 11:45:00 GMT</pubDate>
<description>Oxford Biomedica PLC has applied to the London Stock Exchange for the admission to trading of 92,381 ordinary shares, issued under its Long Term Incentive Plan, Sharesave Scheme, and Employee Share Option Scheme. These new ordinary shares are expected to be admitted to trading on March 9, 2026, and will rank equally with existing shares.
Disclaimer*</description>
</item>
<item>
<title>Capital Markets Day and investor conferences</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/capital-markets-day-and-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/capital-markets-day-and-investor-conferences</guid>
<pubDate>Tue, 03 Mar 2026 07:00:00 GMT</pubDate>
<description>Oxford Biomedica PLC has announced its Capital Markets Day will be held on June 2, 2026, at the London Stock Exchange Group headquarters. The company will also participate in several upcoming investor conferences, including the UBS European Healthcare Conference on March 3-4, 2026, the Berenberg UK Corporate Conference on March 17-19, 2026, the Needham Virtual Healthcare Conference on April 13-16, 2026, and the Berenberg Midsummer Midcaps Conference on June 4-5, 2026. Additionally, Oxford Biomed</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/total-voting-rights-324</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/total-voting-rights-324</guid>
<pubDate>Mon, 02 Mar 2026 07:00:00 GMT</pubDate>
<description>Oxford Biomedica PLC has announced its total voting rights as of February 28, 2026, which stands at 120,873,439 ordinary shares of 50 pence each, with no shares held in treasury. This figure of 120,873,439 will serve as the denominator for shareholders calculating their notification requirements under the FCA's Disclosure Guidance and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>Response to Rule 2.8 Announcement</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/response-to-rule-28-announcement-2</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/response-to-rule-28-announcement-2</guid>
<pubDate>Wed, 25 Feb 2026 12:33:00 GMT</pubDate>
<description>Oxford Biomedica plc announced that EQT X EUR SCSp and EQT X USD SCSp have confirmed they do not intend to make an offer for the company, thus are bound by Rule 2.8 of the City Code on Takeovers and Mergers. The Board had previously considered and unanimously rejected four proposals from EQT, including cash offers and a share alternative, as they undervalued the company and its prospects. Oxford Biomedica expressed confidence in its leadership, future prospects, and continued progress towards fi</description>
</item>
<item>
<title>Disclosure Table</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/disclosure-table-24</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/disclosure-table-24</guid>
<pubDate>Wed, 25 Feb 2026 12:12:00 GMT</pubDate>
<description>The Takeover Panel has updated its Disclosure Table, noting the commencement of an offer period for Augmentum Fintech plc by Frontier Bidco Limited, which is indirectly controlled by Verdane Fund Manager AB. Additionally, the offer period for Oxford Biomedica plc by EQT X EUR SCSp and EQT X USD SCSp has concluded, with the Rule 2.6 deadline having passed on February 25, 2026. Several other offer periods remain active, with various offerors identified for companies such as Beazley plc, CAB Paymen</description>
</item>
<item>
<title>Rule 2.8 Announcement</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/rule-28-announcement-5</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/rule-28-announcement-5</guid>
<pubDate>Wed, 25 Feb 2026 12:00:00 GMT</pubDate>
<description>EQT Fund Management S.à r.l. has announced that it does not intend to make an offer for Oxford Biomedica plc, following previous consideration of a possible bid. This statement, made under Rule 2.8 of the City Code on Takeovers and Mergers, means EQT and its concert parties are restricted from making a further offer for Oxford Biomedica for six months, unless certain conditions are met, such as agreement from Oxford Biomedica's board or a competing offer from a third party.
Discl</description>
</item>
<item>
<title>Full year Trading Update and Notice of Results</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/full-year-trading-update-and-notice-of-results-11</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/full-year-trading-update-and-notice-of-results-11</guid>
<pubDate>Tue, 24 Feb 2026 07:03:00 GMT</pubDate>
<description>Oxford Biomedica PLC expects full-year 2025 revenues to be at the upper end of guidance at £166-169 million, a c.30% increase from £128.8 million in 2024, and anticipates achieving mid-to-high single-digit £ million Operating EBITDA profitability, including a non-recurring gain from an acquisition. The contracted value of client orders rose 20% to £224 million, and the company reiterates its 2026 revenue guidance of £220-240 million, forecasting continued strong growth and expanding EBITDA margi</description>
</item>
<item>
<title>Rule 2.9 Announcement</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/rule-29-announcement-38</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/rule-29-announcement-38</guid>
<pubDate>Thu, 19 Feb 2026 09:44:00 GMT</pubDate>
<description>Oxford Biomedica plc announced on February 19, 2026, that as of February 18, 2026, its issued share capital comprised 120,873,439 ordinary shares of £0.50 each, with no shares held in treasury, in accordance with Rule 2.9 of the City Code on Takeovers and Mergers. This disclosure is relevant for potential takeover activity and requires persons interested in 1% or more of the company's securities to make specific disclosures under the Code.
Disclaimer*</description>
</item>
<item>
<title>Extension of PUSU Deadline</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/extension-of-pusu-deadline-8</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/extension-of-pusu-deadline-8</guid>
<pubDate>Wed, 11 Feb 2026 15:01:00 GMT</pubDate>
<description>Oxford Biomedica plc has announced an extension to the PUSU (Put Up or Shut Up) deadline for EQT X EUR SCSp and EQT X USD SCSp, who made an unsolicited approach regarding a possible cash offer for the company. The preliminary discussions between Oxford Biomedica and EQT are ongoing, and the Takeover Panel has consented to extend the deadline for EQT to announce a firm intention to make an offer, or to confirm they do not intend to make an offer, to 5:00 pm on 25 February 2026. There is no certai</description>
</item>
<item>
<title>Multi-year supply agreement with BMS</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/multi-year-supply-agreement-with-bms</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/multi-year-supply-agreement-with-bms</guid>
<pubDate>Wed, 04 Feb 2026 07:00:00 GMT</pubDate>
<description>Oxford Biomedica PLC has signed a new multi-year Commercial Supply Agreement with Bristol Myers Squibb to become the commercial manufacturer of lentiviral vectors for BMS' CAR-T programmes, with an initial five-year term and an option to extend. This expanded partnership, building on a previous agreement from March 2020, is expected to commence commercial manufacturing in 2026, subject to regulatory approval, and will take place at OXB's facilities in Oxford, UK, and Durham, NC, US. The agreemen</description>
</item>
<item>
<title>Response to press speculation</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/response-to-press-speculation-20</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/response-to-press-speculation-20</guid>
<pubDate>Wed, 14 Jan 2026 16:49:00 GMT</pubDate>
<description>Oxford Biomedica plc has confirmed it received an unsolicited approach from EQT regarding a possible cash offer for the company's entire share capital, following earlier rejected proposals that were deemed to undervalue the business. The two parties are now in preliminary discussions to determine if an offer can be made at a recommendable level, with EQT required to announce a firm intention to make an offer or withdraw by 5:00 p.m. on February 11, 2026. Oxford Biomedica's issued share capital a</description>
</item>
<item>
<title>Block Listing Return</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/block-listing-return-19</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/block-listing-return-19</guid>
<pubDate>Fri, 02 Jan 2026 07:00:00 GMT</pubDate>
<description>Oxford Biomedica PLC has reported on its employee share schemes for the period of July 1, 2025, to December 31, 2025. Under the 2015 Employee Share Option Scheme, 13,800 securities were issued, leaving a balance of 267,036 unallotted securities. The 2015 and 2024 Long Term Incentive Plan saw 362,154 securities issued, resulting in 628,075 remaining unallotted. For the 2015 and 2024 Deferred Bonus Plan, 128,536 securities were issued, with 393,913 unallotted. Finally, the Sharesave Scheme had 190</description>
</item>
<item>
<title>PDMR Dealing</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/pdmr-dealing-44</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/pdmr-dealing-44</guid>
<pubDate>Mon, 08 Dec 2025 15:15:00 GMT</pubDate>
<description>Oxford Biomedica plc announced that Chief People Officer Lisa Doman and Chief Innovation Officer Kyriacos Mitrophanous each exercised 3,057 SAYE 2022 options at £2.944 per share on December 8, 2025, and subsequently sold their respective 3,057 ordinary shares at an average price of £6.23026 per share, resulting in a total sale value of £19,045.90 for each individual.
Disclaimer*</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/oxford-biomedica-plc/news/holdings-in-company-805</link>
<guid isPermaLink="true">https://6ix.com/company/oxford-biomedica-plc/news/holdings-in-company-805</guid>
<pubDate>Mon, 03 Nov 2025 16:55:00 GMT</pubDate>
<description>M&G Plc has notified Oxford Biomedica PLC on November 3, 2025, that it crossed below the notifiable threshold on October 31, 2025, regarding voting rights. M&G Plc now holds 4.987708% of the voting rights attached to shares, a decrease from the previously notified 5.024244%. This represents a total of 6,010,039 voting rights held in the issuer. The change is due to a disposal of voting rights, and M&G Plc no longer holds a notifiable interest.
Disclaimer*</description>
</item>
</channel>
</rss>